Journal
THERANOSTICS
Volume 9, Issue 7, Pages 1923-1951Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.30787
Keywords
berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics
Categories
Funding
- National Nature Science Foundation of China [81603339, 81602344]
- Natural Science Foundation of Anhui Province [1708085QH175]
- American Heart Association [18CDA34110359]
- Slovenian Research Agency ARRS [J3-8209]
- Institute of Health Carlos III [CIBEROBN CB12/03/30038]
Ask authors/readers for more resources
Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available